LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
list after determining that Lilly's supply is currently meeting or exceeding demand and will continue to do so in the future. The regulatory body concluded that the shortage of tirzepatide medicines is now resolved. The stock is gaining in the pre-market hours in response to the encouraging news. Lilly markets tirzepatide, a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA), as Mounjaro for type II diabetes (T2D) and Zepbound for obesity. Per the regulatory body, a “shortage” is defined as a period of time when the demand or projected demand for the drug within the United States exceeds the supply of the drug. The tirzepatide medicines were added to the FDA's shortage list in 2022 due to Lilly's supply shortage. In October 2024, the agency removed tirzepatide injection products from its shortage list after determining that the issue was resolved. However, the Outsourcing Facilities Association, a trade association representing compounding pharmacists and facilities filed a lawsui
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- US Approves First Drug Treatment For Sleep Apnea [Barron's]Barrons
- FDA approves weight-loss drug Zepbound for obstructive sleep apnea [CNN]CNN
- Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints [Yahoo! Finance]Yahoo! Finance
- FDA approves weight loss drug Zepbound for sleep apnea [MSNBC.com]MSNBC.com
- FDA Approves First Medication for Obstructive Sleep Apnea [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/24 - Miss
LLY
Sec Filings
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- LLY's page on the SEC website